Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma
Clinical trial NCT02077114 · COMPLETED
Trial details
- NCT number
- NCT02077114
- Sponsor
- Herlev Hospital
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-02-01
- Primary completion
- 2014-09-01
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.